Article
Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity.
Cancer immunology research - 1 May 2021
Phadke Manali S, Chen Zhihua, Li Jiannong, Mohamed Eslam, Davies Michael A, Smalley Inna, Duckett Derek R, Palve Vinayak, Czerniecki Brian J, Forsyth Peter A, Noyes David, Adeegbe Dennis O, Eroglu Zeynep, Nguyen Kimberly T, Tsai Kenneth Y, Rix Uwe, Burd Christin E, Chen Yian A, Rodriguez Paulo C, Smalley Keiran S M
Abstract excerpt
Immunotherapy (IT) and targeted therapy (TT) are both effective against melanoma, but their combination is frequently toxic. Here, we investigated whether the sequence of IT (anti-PD-1)→ TT (ceritinib-trametinib or dabrafenib-trametinib) was associated with improved antitumor responses in mouse models of BRAF- and NRAS-mutant melanoma. Mice with NRAS-mutant (SW1) or BRAF-mutant (SM1) mouse melanomas were treated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.